Industry

TREASURE topline results show evidence of therapeutic impact Study preliminary results analyses indicate good potential for favorable results in Athersys’ MASTERS-2 study Conference call today at 8:30 a.m. ET CLEVELAND, Ohio–(BUSINESS WIRE)–$ATHX #Athersys–Athersys, Inc. (Nasdaq: ATHX) announced today that its partner, HEALIOS K.K. (Healios), has reported topline results for its Japan ischemic stroke study, TREASURE. … [Read more…]

LONDON–(BUSINESS WIRE)–Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds a new era in digital medicine. The NICE guidance states that Sleepio, Big Health’s digital therapeutic … [Read more…]

BRUSSELS–(BUSINESS WIRE)–Yesterday, the Platform for Better Preventive Healthcare organised a policy briefing “What are the next steps for the EU addictions policy”, hosted by Czech Member of the European Parliament (MEP) Radka Maxová (Socialists and Democrats). The briefing gathered healthcare experts and political stakeholders to discuss the Report of the Special Committee on Beating Cancer … [Read more…]

PORTLAND, Ore.–(BUSINESS WIRE)–#healthcare–In the race to retain employees in a competitive market, medZERO’s innovative app-based healthcare funding solution is an increasingly attractive add-on benefit for employers. “In this competitive job market, we want to do everything we can to attract and retain the best employees,” said Candace Atnip, Chief People Officer for Bamboo Sushi. “medZERO’s … [Read more…]

BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc. (HKEX:1228), a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, today announced that it will participate in the Morgan Stanley Virtual China Summit 2022 to be held on May 24-26, 2022. About CANbridge Pharmaceuticals Inc. CANbridge Pharmaceuticals … [Read more…]

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will be participating in the upcoming Stifel Jaws and Paws Conference. Bjarne Bergheim, President & Chief Executive Officer, and Michael Watts, Chief Financial Officer, are scheduled to present on Wednesday, June 1 at … [Read more…]

Available on iTero Element Plus series scanners and imaging systems. Advanced algorithms generate realistic simulations of Invisalign treatment outcomes, available in both in-face and 3D dentition views, to help drive patient education and treatment acceptance. TEMPE, Ariz. & MIAMI & COPENHAGEN, Denmark & LONDON–(BUSINESS WIRE)–Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device … [Read more…]

The signed agreement establishes beachhead to broadly market and distribute Tru Niagen® to Mainland China’s aging population LOS ANGELES–(BUSINESS WIRE)–$CDXC #NAD–ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the “JV Agreement”) to establish a joint venture through its wholly owned subsidiary ChromaDex … [Read more…]

LEEDS, UK,–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma, will present at the H.C. Wainwright Global Investment Conference. The presentation will be available for … [Read more…]

LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of … [Read more…]